Corporate Profile

Rhythm is a biopharmaceutical company focused on developing and commercializing peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. More >>

Recent NewsMore >>
Rhythm Pharmaceuticals Announces Progress in Clinical Development of Setmelanotide for Treatment of Rare Genetic Disorders of Obesity
Rhythm Pharmaceuticals Reports Third Quarter 2017 Financial Results
Rhythm Announces Preliminary Data from Phase 2 Study of Setmelanotide for Treatment of Bardet-Biedl Syndrome
RYTM (Common Stock) $26.050.00 (0.00%)02/21/18 4:00 p.m. ET
Stock chart for: RYTM.O.  Currently trading at $26.05 with a 52 week high of $33.81 and a 52 week low of $21.38.
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources
Upcoming EventsMore >>
There are currently no events scheduled.